Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024

In 2024, the FDA approved 27 innovative small-molecule drugs, including significant treatments for conditions like severe alopecia areata, non-small cell lung cancer, and nonalcoholic steatohepatitis (NASH). Notable drugs include Rezdiffra, which targets liver-specific thyroid hormone receptors for NASH, and Leqselvi, a JAK inhibitor that demonstrated significant hair regrowth in severe alopecia areata trials with 1,220 participants. Other approvals, such as Tryvio for hypertension and Vafseo for anemia in chronic kidney disease, address critical treatment gaps. These advancements highlight ongoing innovation in drug development, offering new therapeutic options across various medical fields.